What is Leerink Partnrs’ Forecast for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.29) EPS.

Separately, Guggenheim assumed coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Price Performance

Eledon Pharmaceuticals stock opened at $3.37 on Tuesday. Eledon Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $5.54. The stock has a market capitalization of $201.80 million, a PE ratio of -1.68 and a beta of 0.80. The firm has a 50 day simple moving average of $4.14 and a 200-day simple moving average of $3.88.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the previous year, the company posted ($1.00) EPS.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ELDN. Geode Capital Management LLC grew its stake in shares of Eledon Pharmaceuticals by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after purchasing an additional 33,569 shares during the last quarter. Kera Capital Partners Inc. bought a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at $106,000. Inspire Investing LLC acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter valued at $802,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Eledon Pharmaceuticals by 100.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company’s stock worth $124,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Eledon Pharmaceuticals during the fourth quarter worth $82,000. 56.77% of the stock is currently owned by institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).